Live
FierceBiotechChutes & Ladders—Former FDA leader takes new biotech TurnFierceBiotechASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancerEndpoints News#ASCO26: Merck partner Kelun outlines Phase 3 lung cancer success in China studyEndpoints News#ASCO26: Key head and neck cancer readouts from J&J, Corbus, Summit, Akero and BicaraEndpoints News#ASCO26: New data released for VEGF bispecifics from BioNTech-BMS, Pfizer-3SBioScienceAncient wars between microbes gave us key immune defensesClinical OMICsNext-Generation Cardiac AI System Outperforms Existing ModelsClinical OMICsOpen-Source Algorithm Advances Precision Menstrual Health Beyond FertilityEndpoints NewsHow a group of biotechs ran a covert campaign to push out the FDA commissionerClinical OMICsOncology’s Next AI Battleground: Instant Clinical and Commercial InsightBioWorldAppointments and advancements for May 21, 2026BioWorldFinancings for May 21, 2026
BioWorld Mar 18, 2026

CSPC Zhongqi Pharmaceutical Technology synthesizes PDE4B2 inhibitors

CSPC Zhongqi Pharmaceutical Technology synthesizes PDE4B2 inhibitors

Original
Body unavailable. Use the original source.